{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=4", "query": { "condition": "Renal Tumors", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1794, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T21:09:05.725Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05708950", "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Solid Tumor", "Melanoma", "Carcinoma", "Sarcoma", "Lung Cancer", "Prostate Cancer", "Breast Cancer", "Colo-rectal Cancer", "Uterine Cancer", "Pancreatic Cancer", "Gastric Cancer", "Esophageal Cancer", "Thyroid Cancer", "Ovarian Cancer", "Kidney Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "KVA12123 - Dose Escalation", "type": "DRUG" }, { "name": "KVA12123 Plus Pembrolizumab - Dose Escalation", "type": "DRUG" }, { "name": "KVA12123 - Dose Expansion", "type": "DRUG" }, { "name": "KVA12123 Plus Pembrolizumab - Dose Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kineta Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-03-03", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 7, "location_summary": "Santa Monica, California • Denver, Colorado • Sarasota, Florida + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05708950" }, { "nct_id": "NCT05820087", "title": "The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Renal Cancer", "Tumor, Solid", "Kidney Cancer", "Tumor", "Tumor, Benign" ], "interventions": [ { "name": "HistoSonics Edison System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "HistoSonics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 67, "start_date": "2024-01-04", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 15, "location_summary": "Los Angeles, California • Mission Viejo, California • New Haven, Connecticut + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Celebration", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05820087" }, { "nct_id": "NCT01198158", "title": "Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2010-09-15", "completion_date": "2017-12-16", "has_results": true, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 524, "location_summary": "Scottsdale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 354 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01198158" }, { "nct_id": "NCT07224776", "title": "Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Proteinuric Renal Disease", "Proteinuric Kidney Disease", "Proteinuria", "Proteinuria in Nephrotic Range" ], "interventions": [ { "name": "sparsentan", "type": "DRUG" }, { "name": "No sparsentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-07-10", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224776" }, { "nct_id": "NCT00376987", "title": "Zinc Supplements in Lowering Cadmium Levels in Smokers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Cervical Cancer", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Kidney Cancer", "Leukemia", "Liver Cancer", "Lung Cancer", "Pancreatic Cancer", "Tobacco Use Disorder" ], "interventions": [ { "name": "zinc oxide", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "21 Years to 120 Years" }, "enrollment_count": 61, "start_date": "2003-12", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376987" }, { "nct_id": "NCT04022343", "title": "Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-08-06", "completion_date": "2026-12-09", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04022343" }, { "nct_id": "NCT01933789", "title": "Improving Communication About Serious Illness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Critical Illness", "Chronic Disease", "Terminal Care", "Palliative Care", "Communication", "Advance Care Planning", "Neoplasm Metastasis", "Lung Neoplasms", "Pulmonary Disease, Chronic Obstructive", "Heart Failure", "End Stage Liver Disease", "Kidney Failure, Chronic" ], "interventions": [ { "name": "Communication Feedback Form for Patients with Serious Illness", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 817, "start_date": "2013-09", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 6, "location_summary": "Renton, Washington • Seattle, Washington", "locations": [ { "city": "Renton", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933789" }, { "nct_id": "NCT03798626", "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastroesophageal Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Gevokizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 167, "start_date": "2019-05-22", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 3, "location_summary": "Los Angeles, California • St Louis, Missouri • Nashville, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03798626" }, { "nct_id": "NCT03284385", "title": "Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Locally Advanced Clear Cell Renal Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-01-29", "completion_date": "2027-04-22", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 29, "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 18 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03284385" }, { "nct_id": "NCT01136733", "title": "A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 173, "start_date": "2010-08-05", "completion_date": "2018-02-08", "has_results": true, "last_update_posted_date": "2019-02-27", "last_synced_at": "2026-10-09T21:09:05.725Z", "location_count": 14, "location_summary": "Tucson, Arizona • Orange, California • San Diego, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01136733" } ] }